Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial
Xenon Pharmaceuticals announced initiation of a Phase 1 “first-in-human” clinical trial of its proprietary epilepsy product candidate, XEN1101, which is an orally administered Kv7 potassium channel opener that has the potential to treat both adult as well as rare pediatric genetic forms of epilepsy. October 17, 2017